Brief: Syndax Pharmaceuticals Q4 EPS USD -1
27/02/2024 21:06
Feb 27 (Reuters) - Syndax Pharmaceuticals Q4 operating expenses USD 77.905 million. * Q4 operating income USD -77.905 million * Q4 net income USD -72.473 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million